Recently spun out from UK-based Cambridge Cognition Holdings plc with 15-months’ worth of working seed capital, CNS-focused Monument Therapeutics is now working to put two repurposed and reformulated compounds into the clinic next year, one to treat cognitive impairment in schizophrenia and another for post-operative cognitive dysfunction, or POCD, a condition arising from major surgery.
Monument raised £2.6m in seed funding in June to further its development strategy of leveraging digital assessments of cognition to...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
